Characterization of a Type-common Human Recombinant Monoclonal Antibody to Herpes Simplex Virus with High Therapeutic Potential

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 1998 Oct 17

PMID 9774565

Citations 18

Authors

A De Logu

R A Williamson

R Rozenshteyn

F Ramiro-Ibanez

C D Simpson

D R Burton

P P Sanna

Affiliations

Soon will be listed here.

Abstract

We report the characterization of a type-common human recombinant monoclonal antibody previously isolated by antigen selection from a phage-displayed combinatorial antibody library established from a herpes simplex virus (HSV)-seropositive individual. Competition with well-characterized murine monoclonal antibodies and immunodetection of gD truncations revealed that this antibody recognizes the group Ib antigenic site of glycoprotein D, a highly conserved and protective type-common determinant. To our knowledge, this is the first human group Ib monoclonal antibody ever described. The antibody also displayed first-order neutralization kinetics and a high neutralization rate constant, was capable of completely inhibiting syncytium formation by a fusogenic strain of HSV type 1, and efficiently neutralized low-passage clinical isolates of both HSV serotypes. Taken together with our earlier observations of the in vivo antiviral activities of this human recombinant antibody in animal models of HSV infection, the present results support the high therapeutic potential of this antibody.

Citing Articles

Targeting Herpes Simplex Virus Glycoprotein D with Bispecific Antibodies: Expanding Therapeutic Horizons by Searching for Synergy.

Atanasiu D, Saw W, Friedman H, Cohen G Viruses. 2025; 17(2).

PMID: 40007004 PMC: 11860751. DOI: 10.3390/v17020249.

Effector functions are required for broad and potent protection of neonatal mice with antibodies targeting HSV glycoprotein D.

Slein M, Backes I, Garland C, Kelkar N, Leib D, Ackerman M Cell Rep Med. 2024; 5(2):101417.

PMID: 38350452 PMC: 10897633. DOI: 10.1016/j.xcrm.2024.101417.

A self-binding immune complex vaccine elicits strong neutralizing responses against herpes simplex virus in mice.

Diamos A, Pardhe M, Bergeman M, Kamzina A, DiPalma M, Aman S Front Immunol. 2023; 14:1085911.

PMID: 37205110 PMC: 10186352. DOI: 10.3389/fimmu.2023.1085911.

Maternally transferred mAbs protect neonatal mice from HSV-induced mortality and morbidity.

Backes I, Byrd B, Slein M, Patel C, Taylor S, Garland C J Exp Med. 2022; 219(12).

PMID: 36156707 PMC: 9516843. DOI: 10.1084/jem.20220110.

Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial.

Politch J, Cu-Uvin S, Moench T, Tashima K, Marathe J, Guthrie K PLoS Med. 2021; 18(2):e1003495.

PMID: 33534791 PMC: 7857576. DOI: 10.1371/journal.pmed.1003495.

References

Nugier F, Colin J, Aymard M, Langlois M . Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol. 1992; 36(1):1-12. DOI: 10.1002/jmv.1890360102. View

Dimmock N . Neutralization of animal viruses. Curr Top Microbiol Immunol. 1993; 183:1-149. DOI: 10.1007/978-3-642-77849-0. View

DULBECCO R, Vogt M, Strickland A . A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus. Virology. 1956; 2(2):162-205. DOI: 10.1016/0042-6822(56)90017-4. View

Liebert U, Schneider-Schaulies S, Baczko K, Ter Meulen V . Antibody-induced restriction of viral gene expression in measles encephalitis in rats. J Virol. 1990; 64(2):706-13. PMC: 249164. DOI: 10.1128/JVI.64.2.706-713.1990. View

Sanna P, De Logu A, Williamson R, Hom Y, Straus S, Bloom F . Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV. Virology. 1996; 215(1):101-6. DOI: 10.1006/viro.1996.0011. View

Prober C, Sullender W, Yasukawa L, Au D, Yeager A, Arvin A . Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med. 1987; 316(5):240-4. DOI: 10.1056/NEJM198701293160503. View

Mofenson L, Moye Jr J . Intravenous immune globulin for the prevention of infections in children with symptomatic human immunodeficiency virus infection. Pediatr Res. 1993; 33(1 Suppl):S80-7; discussion S87-9. DOI: 10.1203/00006450-199305001-00464. View

Kohl S . The role of antibody in herpes simplex virus infection in humans. Curr Top Microbiol Immunol. 1992; 179:75-88. DOI: 10.1007/978-3-642-77247-4_5. View

Sacks S, Wanklin R, Reece D, Hicks K, Tyler K, Coen D . Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity?. Ann Intern Med. 1989; 111(11):893-9. DOI: 10.7326/0003-4819-111-11-893. View

10.

Yoshida T, Suzutani T, Azuma M . Study on the apparent resistant strains of herpes simplex virus type 1 against 9-beta-D-arabinofuranosyladenine. Tohoku J Exp Med. 1988; 156(3):279-90. DOI: 10.1620/tjem.156.279. View

11.

Coen D . The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antiviral Res. 1991; 15(4):287-300. DOI: 10.1016/0166-3542(91)90010-o. View

12.

Christophers J, Sutton R . Characterisation of acyclovir-resistant and -sensitive clinical herpes simplex virus isolates from an immunocompromised patient. J Antimicrob Chemother. 1987; 20(3):389-98. DOI: 10.1093/jac/20.3.389. View

13.

Chanock R, Crowe Jr J, Murphy B, Burton D . Human monoclonal antibody Fab fragments cloned from combinatorial libraries: potential usefulness in prevention and/or treatment of major human viral diseases. Infect Agents Dis. 1993; 2(3):118-31. View

14.

Norris S, Kessler H, Fife K . Severe, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS. J Infect Dis. 1988; 157(1):209-10. DOI: 10.1093/infdis/157.1.209. View

15.

Skull S, Kemp A . Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. Arch Dis Child. 1996; 74(6):527-30. PMC: 1511572. DOI: 10.1136/adc.74.6.527. View

16.

Della-Porta A, WESTAWAY E . A multi-hit model for the neutralization of animal viruses. J Gen Virol. 1978; 38(1):1-19. DOI: 10.1099/0022-1317-38-1-1. View

17.

Parren P, Ditzel H, Gulizia R, Binley J, Barbas 3rd C, Burton D . Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS. 1995; 9(6):F1-6. DOI: 10.1097/00002030-199506000-00001. View

18.

Crowe Jr J, Murphy B, Chanock R, Williamson R, Barbas 3rd C, Burton D . Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci U S A. 1994; 91(4):1386-90. PMC: 43163. DOI: 10.1073/pnas.91.4.1386. View

19.

Sanna P, Williamson R, De Logu A, Bloom F, Burton D . Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries. Proc Natl Acad Sci U S A. 1995; 92(14):6439-43. PMC: 41533. DOI: 10.1073/pnas.92.14.6439. View

20.

Lodmell D, Niwa A, Hayashi K, Notkins A . Prevention of cell-to-cell spread of herpes simplex virus by leukocytes. J Exp Med. 1973; 137(3):706-20. PMC: 2139378. DOI: 10.1084/jem.137.3.706. View